Raymond James Financial
KLRS

Raymond James Financial’s Kalaris Therapeutics KLRS Stock Holding History

Raymond James Financial’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$395K Sell
97,164
-21,723
-18% -$113K ﹤0.01% 4666
2026
Q1 		$686K Buy
118,887
+30,451
+34% +$270K ﹤0.01% 4125
2025
Q4 		$746K Buy
+88,436
New +$565K ﹤0.01% 3980
2025
Q3 		– Sell
-2,629
Closed -$7.02K – 7008
2025
Q2 		$7.02K Buy
+2,629
New +$11.9K ﹤0.01% 6056
2025
Q1 		– Sell
-2,630
Closed -$25.4K – 4986
2024
Q4 		$25.4K Buy
+2,630
New +$39.8K ﹤0.01% 4697

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's KLRS Position: Q2 2026 in Review

Raymond James Financial reduced its Kalaris Therapeutics (KLRS) stake by 18% in Q2 2026, selling an estimated $113K and leaving 97,164 shares worth $395K. The position accounts for ﹤0.01% of the portfolio, ranked #4666.

Raymond James Financial first reported a position in KLRS in Q4 2024 and has held it in 5 quarters since. The position peaked at $746K in Q4 2025. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Raymond James Financial held 97,164 shares of Kalaris Therapeutics worth $395K as of Q2 2026.
  • Raymond James Financial sold 21,723 Kalaris Therapeutics shares in Q2 2026, an estimated $113K.
  • Kalaris Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4666 holding.
  • Raymond James Financial first reported a position in Kalaris Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Raymond James Financial's Kalaris Therapeutics position peaked at $746K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.